BR112019020058A2

BR112019020058A2 - formas de cristal inovadoras de um inibidor de pol1

formas de cristal inovadoras de um inibidor de pol1 Download PDF

Info

Publication number: BR112019020058A2
Authority: BR; Brazil
Prior art keywords: crystalline form; crystalline; compound; document; analysis
Prior art date: 2017-03-28

Application number

BR112019020058-4A

Other languages

English (en)

Portuguese (pt)

Inventor

Mustapha Haddach

Original Assignee

Pimera, Inc.

Priority date

2017-03-28

Filing date

2018-03-28

Publication date

2020-07-14

2018-03-28 Application filed by Pimera, Inc. filed Critical Pimera, Inc.

2020-07-14 Publication of BR112019020058A2 publication Critical patent/BR112019020058A2/pt

Links

239000013078 crystal Substances 0.000 title description 28
239000003112 inhibitor Substances 0.000 title description 14
101100117436 Thermus aquaticus polA gene Proteins 0.000 title description 3
239000000203 mixture Substances 0.000 claims abstract description 92
238000000034 method Methods 0.000 claims abstract description 74
150000001875 compounds Chemical class 0.000 claims description 134
238000000634 powder X-ray diffraction Methods 0.000 claims description 92
206010028980 Neoplasm Diseases 0.000 claims description 67
201000011510 cancer Diseases 0.000 claims description 52
238000003860 storage Methods 0.000 claims description 37
239000008194 pharmaceutical composition Substances 0.000 claims description 15
239000003937 drug carrier Substances 0.000 claims description 8
210000004072 lung Anatomy 0.000 claims description 5
210000000496 pancreas Anatomy 0.000 claims description 5
210000004369 blood Anatomy 0.000 claims description 4
239000008280 blood Substances 0.000 claims description 4
210000000481 breast Anatomy 0.000 claims description 4
210000003734 kidney Anatomy 0.000 claims description 4
210000004185 liver Anatomy 0.000 claims description 4
210000002307 prostate Anatomy 0.000 claims description 4
125000005605 benzo group Chemical group 0.000 claims description 3
210000004556 brain Anatomy 0.000 claims description 3
210000001072 colon Anatomy 0.000 claims description 3
210000002216 heart Anatomy 0.000 claims description 3
210000003128 head Anatomy 0.000 claims description 2
210000001165 lymph node Anatomy 0.000 claims description 2
210000003739 neck Anatomy 0.000 claims description 2
210000003491 skin Anatomy 0.000 claims 1
239000007787 solid Substances 0.000 abstract description 25
230000008569 process Effects 0.000 abstract description 12
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 138
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 64
238000004458 analytical method Methods 0.000 description 63
238000000113 differential scanning calorimetry Methods 0.000 description 58
201000010099 disease Diseases 0.000 description 54
239000000463 material Substances 0.000 description 48
150000003839 salts Chemical class 0.000 description 45
238000012216 screening Methods 0.000 description 44
238000011282 treatment Methods 0.000 description 44
239000002904 solvent Substances 0.000 description 40
238000002411 thermogravimetry Methods 0.000 description 39
238000010438 heat treatment Methods 0.000 description 35
238000001907 polarising light microscopy Methods 0.000 description 34
239000003795 chemical substances by application Substances 0.000 description 32
239000003814 drug Substances 0.000 description 31
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
238000005481 NMR spectroscopy Methods 0.000 description 29
241000124008 Mammalia Species 0.000 description 27
238000004455 differential thermal analysis Methods 0.000 description 25
238000001757 thermogravimetry curve Methods 0.000 description 25
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 24
239000002002 slurry Substances 0.000 description 21
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
230000001225 therapeutic effect Effects 0.000 description 19
238000004519 manufacturing process Methods 0.000 description 18
230000002860 competitive effect Effects 0.000 description 17
229940079593 drug Drugs 0.000 description 17
238000001035 drying Methods 0.000 description 17
239000008177 pharmaceutical agent Substances 0.000 description 17
-1 benzo [4,5] imidazo [1 , 2-a] [1, 8] naphthyridine-6-carboxamide Chemical compound 0.000 description 16
210000004027 cell Anatomy 0.000 description 16
238000002425 crystallisation Methods 0.000 description 16
230000008025 crystallization Effects 0.000 description 16
238000009472 formulation Methods 0.000 description 16
238000004128 high performance liquid chromatography Methods 0.000 description 16
239000000243 solution Substances 0.000 description 16
208000024891 symptom Diseases 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
230000004927 fusion Effects 0.000 description 14
238000002360 preparation method Methods 0.000 description 14
238000001144 powder X-ray diffraction data Methods 0.000 description 13
239000000725 suspension Substances 0.000 description 13
229940124597 therapeutic agent Drugs 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
238000002648 combination therapy Methods 0.000 description 12
238000001816 cooling Methods 0.000 description 12
230000000694 effects Effects 0.000 description 12
239000000546 pharmaceutical excipient Substances 0.000 description 12
239000012453 solvate Substances 0.000 description 12
239000012296 anti-solvent Substances 0.000 description 11
230000008901 benefit Effects 0.000 description 10
208000035475 disorder Diseases 0.000 description 10
239000002245 particle Substances 0.000 description 10
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
238000007792 addition Methods 0.000 description 9
239000002552 dosage form Substances 0.000 description 9
230000002265 prevention Effects 0.000 description 9
230000004044 response Effects 0.000 description 9
238000013518 transcription Methods 0.000 description 9
230000035897 transcription Effects 0.000 description 9
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
239000002246 antineoplastic agent Substances 0.000 description 8
239000003826 tablet Substances 0.000 description 8
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
239000002253 acid Substances 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
238000002844 melting Methods 0.000 description 7
230000008018 melting Effects 0.000 description 7
238000001953 recrystallisation Methods 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
239000002671 adjuvant Substances 0.000 description 6
230000033115 angiogenesis Effects 0.000 description 6
238000011284 combination treatment Methods 0.000 description 6
238000004090 dissolution Methods 0.000 description 6
238000001704 evaporation Methods 0.000 description 6
230000008020 evaporation Effects 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007788 liquid Substances 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
230000002062 proliferating effect Effects 0.000 description 6
239000012047 saturated solution Substances 0.000 description 6
238000001179 sorption measurement Methods 0.000 description 6
239000003381 stabilizer Substances 0.000 description 6
239000007858 starting material Substances 0.000 description 6
230000002195 synergetic effect Effects 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
230000002159 abnormal effect Effects 0.000 description 5
239000000654 additive Substances 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
230000004663 cell proliferation Effects 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
230000007613 environmental effect Effects 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
230000003993 interaction Effects 0.000 description 5
239000000843 powder Substances 0.000 description 5
239000003755 preservative agent Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
239000000375 suspending agent Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
241000196324 Embryophyta Species 0.000 description 4
208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 4
241000288906 Primates Species 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
208000025865 Ulcer Diseases 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000003963 antioxidant agent Substances 0.000 description 4
230000006907 apoptotic process Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
230000008859 change Effects 0.000 description 4
229940127089 cytotoxic agent Drugs 0.000 description 4
238000004807 desolvation Methods 0.000 description 4
238000011161 development Methods 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
206010023332 keratitis Diseases 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
210000001672 ovary Anatomy 0.000 description 4
230000009467 reduction Effects 0.000 description 4
201000000306 sarcoidosis Diseases 0.000 description 4
238000013112 stability test Methods 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
239000002562 thickening agent Substances 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
238000011277 treatment modality Methods 0.000 description 4
238000011269 treatment regimen Methods 0.000 description 4
206010012689 Diabetic retinopathy Diseases 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
235000010643 Leucaena leucocephala Nutrition 0.000 description 3
240000007472 Leucaena leucocephala Species 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
206010038933 Retinopathy of prematurity Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
239000002168 alkylating agent Substances 0.000 description 3
229940100198 alkylating agent Drugs 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
239000002178 crystalline material Substances 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
206010020718 hyperplasia Diseases 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
208000014674 injury Diseases 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
230000036407 pain Effects 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000006187 pill Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
230000009696 proliferative response Effects 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
208000016261 weight loss Diseases 0.000 description 3
230000004580 weight loss Effects 0.000 description 3
VOXBZHOHGGBLCQ-UHFFFAOYSA-N 2-amino-3,7-dihydropurine-6-thione;hydrate Chemical compound O.N1C(N)=NC(=S)C2=C1N=CN2.N1C(N)=NC(=S)C2=C1N=CN2 VOXBZHOHGGBLCQ-UHFFFAOYSA-N 0.000 description 2
OOFGUUKYOQBEPU-UHFFFAOYSA-N 3-ethyl-2-(4-methyl-1,4-diazepan-1-yl)benzimidazolo[1,2-a][1,8]naphthyridine-6-carboxylic acid Chemical compound C(C)C=1C(=NC2=C(C=C(C3=NC=4C=CC=CC=4N23)C(=O)O)C=1)N1CCN(CCC1)C OOFGUUKYOQBEPU-UHFFFAOYSA-N 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
201000007815 Bannayan-Riley-Ruvalcaba syndrome Diseases 0.000 description 2
206010004146 Basal cell carcinoma Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
102000043139 CK2 family Human genes 0.000 description 2
108091054872 CK2 family Proteins 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
206010011017 Corneal graft rejection Diseases 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
208000010412 Glaucoma Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
208000022559 Inflammatory bowel disease Diseases 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
QPJBONAWFAURGB-UHFFFAOYSA-L Lobenzarit disodium Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1NC1=CC(Cl)=CC=C1C([O-])=O QPJBONAWFAURGB-UHFFFAOYSA-L 0.000 description 2
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
101150046160 POL1 gene Proteins 0.000 description 2
229930012538 Paclitaxel Natural products 0.000 description 2
206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
208000021386 Sjogren Syndrome Diseases 0.000 description 2
208000000453 Skin Neoplasms Diseases 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
230000007815 allergy Effects 0.000 description 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
230000002491 angiogenic effect Effects 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
210000000013 bile duct Anatomy 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
229940125904 compound 1 Drugs 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
238000001914 filtration Methods 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
235000013305 food Nutrition 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
230000003862 health status Effects 0.000 description 2
201000005787 hematologic cancer Diseases 0.000 description 2
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
229940125697 hormonal agent Drugs 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
229940043355 kinase inhibitor Drugs 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
230000007774 longterm Effects 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
208000002780 macular degeneration Diseases 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000002483 medication Methods 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
239000000155 melt Substances 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
238000002156 mixing Methods 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
210000004789 organ system Anatomy 0.000 description 2
229960001592 paclitaxel Drugs 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000003757 phosphotransferase inhibitor Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000002028 premature Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
210000000664 rectum Anatomy 0.000 description 2
238000010992 reflux Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
201000000849 skin cancer Diseases 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000007901 soft capsule Substances 0.000 description 2
239000011343 solid material Substances 0.000 description 2
238000007614 solvation Methods 0.000 description 2
206010041823 squamous cell carcinoma Diseases 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
230000008685 targeting Effects 0.000 description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
238000011285 therapeutic regimen Methods 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
229960003087 tioguanine Drugs 0.000 description 2
239000008181 tonicity modifier Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000007704 transition Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
208000009999 tuberous sclerosis Diseases 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
210000003932 urinary bladder Anatomy 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 1
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
ZZKNRXZVGOYGJT-VKHMYHEASA-N (2s)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 description 1
FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
NYPGBHKJFKQTIY-TYYBGVCCSA-N 2-cyanoethylazanium;(e)-4-hydroxy-4-oxobut-2-enoate Chemical compound NCCC#N.OC(=O)\C=C\C(O)=O NYPGBHKJFKQTIY-TYYBGVCCSA-N 0.000 description 1
CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
BOCATKBAKISRLA-UHFFFAOYSA-N 4-propyl-5-pyridin-4-yl-3h-1,3-oxazol-2-one Chemical compound N1C(=O)OC(C=2C=CN=CC=2)=C1CCC BOCATKBAKISRLA-UHFFFAOYSA-N 0.000 description 1
IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
MMRCWWRFYLZGAE-ZBZRSYSASA-N 533u947v6q Chemical compound O([C@]12[C@H](OC(C)=O)[C@]3(CC)C=CCN4CC[C@@]5([C@H]34)[C@H]1N(C)C1=C5C=C(C(=C1)OC)[C@]1(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C1)C[C@@](C3)(O)CC)C(=O)N(CCCl)C2=O MMRCWWRFYLZGAE-ZBZRSYSASA-N 0.000 description 1
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
WYRSPZVTTMUNBL-UHFFFAOYSA-N 9h-fluorene-3-carboxylic acid Chemical compound C1=CC=C2C3=CC(C(=O)O)=CC=C3CC2=C1 WYRSPZVTTMUNBL-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000003200 Adenoma Diseases 0.000 description 1
206010001233 Adenoma benign Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
102000012936 Angiostatins Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
102000003989 Aurora kinases Human genes 0.000 description 1
108090000433 Aurora kinases Proteins 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
208000003609 Bile Duct Adenoma Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
208000003163 Cavernous Hemangioma Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
206010008263 Cervical dysplasia Diseases 0.000 description 1
206010061809 Cervix carcinoma stage 0 Diseases 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
208000005590 Choroidal Neovascularization Diseases 0.000 description 1
206010060823 Choroidal neovascularisation Diseases 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
208000000668 Chronic Pancreatitis Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
108010040512 Clupeine Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010055665 Corneal neovascularisation Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
208000012609 Cowden disease Diseases 0.000 description 1
201000002847 Cowden syndrome Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
208000019878 Eales disease Diseases 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
102400001047 Endostatin Human genes 0.000 description 1
108010079505 Endostatins Proteins 0.000 description 1
241000792859 Enema Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
ZPLVYYNMRMBNGE-UHFFFAOYSA-N Eponemycin Natural products CC(C)CCCCC(=O)NC(CO)C(=O)NC(CC(C)=C)C(=O)C1(CO)CO1 ZPLVYYNMRMBNGE-UHFFFAOYSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
241000282324 Felis Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
208000004057 Focal Nodular Hyperplasia Diseases 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
208000007569 Giant Cell Tumors Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
201000010915 Glioblastoma multiforme Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
244000060234 Gmelina philippensis Species 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
239000007821 HATU Substances 0.000 description 1
208000002927 Hamartoma Diseases 0.000 description 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010019629 Hepatic adenoma Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
102100021866 Hepatocyte growth factor Human genes 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
201000002563 Histoplasmosis Diseases 0.000 description 1
101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 1
101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 1
101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
206010051151 Hyperviscosity syndrome Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
208000009164 Islet Cell Adenoma Diseases 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
206010023126 Jaundice Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
206010023330 Keloid scar Diseases 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
208000022010 Lhermitte-Duclos disease Diseases 0.000 description 1
206010024612 Lipoma Diseases 0.000 description 1
208000002404 Liver Cell Adenoma Diseases 0.000 description 1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000007054 Medullary Carcinoma Diseases 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
208000024599 Mooren ulcer Diseases 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010062207 Mycobacterial infection Diseases 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
201000004404 Neurofibroma Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
206010051081 Nodular regenerative hyperplasia Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
102000038030 PI3Ks Human genes 0.000 description 1
108091007960 PI3Ks Proteins 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
241000282579 Pan Species 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010033647 Pancreatitis acute Diseases 0.000 description 1
206010033649 Pancreatitis chronic Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000004788 Pars Planitis Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108010013639 Peptidoglycan Proteins 0.000 description 1
102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000004211 Platelet factor 4 Human genes 0.000 description 1
108090000778 Platelet factor 4 Proteins 0.000 description 1
229940123066 Polymerase inhibitor Drugs 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
229940079156 Proteasome inhibitor Drugs 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
208000007531 Proteus syndrome Diseases 0.000 description 1
206010037075 Protozoal infections Diseases 0.000 description 1
201000002154 Pterygium Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
208000007135 Retinal Neovascularization Diseases 0.000 description 1
206010038848 Retinal detachment Diseases 0.000 description 1
206010038910 Retinitis Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
206010038934 Retinopathy proliferative Diseases 0.000 description 1
241001303601 Rosacea Species 0.000 description 1
206010039705 Scleritis Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241000282887 Suidae Species 0.000 description 1
206010042674 Swelling Diseases 0.000 description 1
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229940123237 Taxane Drugs 0.000 description 1
206010043276 Teratoma Diseases 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
206010043781 Thyroiditis chronic Diseases 0.000 description 1
102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 description 1
108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
201000005485 Toxoplasmosis Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
206010064996 Ulcerative keratitis Diseases 0.000 description 1
102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
206010047663 Vitritis Diseases 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
206010000496 acne Diseases 0.000 description 1
208000004064 acoustic neuroma Diseases 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
201000003229 acute pancreatitis Diseases 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
238000009098 adjuvant therapy Methods 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
102000003801 alpha-2-Antiplasmin Human genes 0.000 description 1
108090000183 alpha-2-Antiplasmin Proteins 0.000 description 1
229960000473 altretamine Drugs 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229960003437 aminoglutethimide Drugs 0.000 description 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
229960002932 anastrozole Drugs 0.000 description 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000001399 anti-metabolic effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003080 antimitotic agent Substances 0.000 description 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
229940045985 antineoplastic platinum compound Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
201000005000 autoimmune gastritis Diseases 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
150000001541 aziridines Chemical class 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
208000003373 basosquamous carcinoma Diseases 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229960000997 bicalutamide Drugs 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
229960001467 bortezomib Drugs 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
239000012267 brine Substances 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
208000003295 carpal tunnel syndrome Diseases 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229960002436 cladribine Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229940126523 co-drug Drugs 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
201000000159 corneal neovascularization Diseases 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000012043 crude product Substances 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
VZFDRQUWHOVFCA-UHFFFAOYSA-L disodium;2-sulfanylbutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S)C([O-])=O VZFDRQUWHOVFCA-UHFFFAOYSA-L 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
229940121647 egfr inhibitor Drugs 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
ZPLVYYNMRMBNGE-TWOQFEAHSA-N eponemycin Chemical compound CC(C)CCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)=C)C(=O)[C@@]1(CO)CO1 ZPLVYYNMRMBNGE-TWOQFEAHSA-N 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
239000003687 estradiol congener Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
YAPCBUZIKBMWLM-UHFFFAOYSA-N ethanol;ethyl acetate;heptane;methanol Chemical compound OC.CCO.CCOC(C)=O.CCCCCCC YAPCBUZIKBMWLM-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
206010016629 fibroma Diseases 0.000 description 1
230000002344 fibroplastic effect Effects 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
230000001497 fibrovascular Effects 0.000 description 1
229960000961 floxuridine Drugs 0.000 description 1
229960005304 fludarabine phosphate Drugs 0.000 description 1
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
229960002074 flutamide Drugs 0.000 description 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
235000008191 folinic acid Nutrition 0.000 description 1
239000011672 folinic acid Substances 0.000 description 1
229960000936 fumagillin Drugs 0.000 description 1
NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
208000024386 fungal infectious disease Diseases 0.000 description 1
230000000855 fungicidal effect Effects 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
201000008361 ganglioneuroma Diseases 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229960003690 goserelin acetate Drugs 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
230000002607 hemopoietic effect Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
201000002735 hepatocellular adenoma Diseases 0.000 description 1
150000004687 hexahydrates Chemical class 0.000 description 1
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
208000013653 hyalitis Diseases 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
230000002390 hyperplastic effect Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
229960000908 idarubicin Drugs 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
208000020658 intracerebral hemorrhage Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000008040 ionic compounds Chemical class 0.000 description 1
201000002529 islet cell tumor Diseases 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
230000035984 keratolysis Effects 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
201000010260 leiomyoma Diseases 0.000 description 1
229960001691 leucovorin Drugs 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
230000002197 limbic effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
238000007726 management method Methods 0.000 description 1
210000004373 mandible Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
229960004296 megestrol acetate Drugs 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000003475 metalloproteinase inhibitor Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
239000013081 microcrystal Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
231100000324 minimal toxicity Toxicity 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000003607 modifier Substances 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
208000027531 mycobacterial infectious disease Diseases 0.000 description 1
206010028537 myelofibrosis Diseases 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
208000001491 myopia Diseases 0.000 description 1
230000004379 myopia Effects 0.000 description 1
208000009091 myxoma Diseases 0.000 description 1
WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 1
BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000035407 negative regulation of cell proliferation Effects 0.000 description 1
201000003142 neovascular glaucoma Diseases 0.000 description 1
208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
229960002653 nilutamide Drugs 0.000 description 1
XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
235000015205 orange juice Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
230000000849 parathyroid Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
229960002340 pentostatin Drugs 0.000 description 1
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
150000003058 platinum compounds Chemical class 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
230000010287 polarization Effects 0.000 description 1
229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 1
201000010065 polycystic ovary syndrome Diseases 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000155 polyglutamine Polymers 0.000 description 1
108010040003 polyglutamine Proteins 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
150000003147 proline derivatives Chemical class 0.000 description 1
239000001294 propane Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229950008679 protamine sulfate Drugs 0.000 description 1
239000003207 proteasome inhibitor Substances 0.000 description 1
238000010926 purge Methods 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
229960004622 raloxifene Drugs 0.000 description 1
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
229940100618 rectal suppository Drugs 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000004264 retinal detachment Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
150000004492 retinoid derivatives Chemical class 0.000 description 1
238000012552 review Methods 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
230000028706 ribosome biogenesis Effects 0.000 description 1
201000004700 rosacea Diseases 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000008299 semisolid dosage form Substances 0.000 description 1
238000011450 sequencing therapy Methods 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
VSHVTYTVMATJOB-UHFFFAOYSA-M sodium 2-(4-methyl-1,4-diazepan-1-yl)benzimidazolo[1,2-a][1,8]naphthyridine-6-carboxylate Chemical compound [Na+].CN1CCN(CCC1)C1=NC2=C(C=C(C3=NC=4C=CC=CC=4N23)C(=O)[O-])C=C1 VSHVTYTVMATJOB-UHFFFAOYSA-M 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
238000002336 sorption--desorption measurement Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
229950001248 squalamine Drugs 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
150000003871 sulfonates Chemical class 0.000 description 1
229960005314 suramin Drugs 0.000 description 1
FIAFUQMPZJWCLV-UHFFFAOYSA-H suramin(6-) Chemical compound [O-]S(=O)(=O)C1=CC(S([O-])(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S([O-])(=O)=O)S([O-])(=O)=O)S([O-])(=O)=O)C)C=CC=3)C)=CC=C(S([O-])(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-H 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000035900 sweating Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
229960003433 thalidomide Drugs 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 description 1
229960001196 thiotepa Drugs 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
229950001139 timonacic Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229960005026 toremifene Drugs 0.000 description 1
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000009529 traumatic brain injury Effects 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
150000004684 trihydrates Chemical class 0.000 description 1
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
230000001173 tumoral effect Effects 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
229960001055 uracil mustard Drugs 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1
229950005839 vinzolidine Drugs 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
239000003643 water by type Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1